ReviewRegenerative therapy2026
Decellularized corneal-based 3D scaffolds: methods decellularization, characterization, mechanical properties, and species source.
Review in Regenerative therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A biomimetic and xeno-free platform for corneal engineering: synergy between PRGF technology and human dental pulp stem cells.Frontiers in bioengineering and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Corneal blindness is a significant worldwide health issue owing to low number of global corneal donors. Decellularized corneal scaffolds intend to be a promising choice for corneal repair by maintaining the native extracellular matrix (ECM) while minimizing immune reactions. This effort comprehensively reviews various decellularization strategies such as physical, chemical, and biological methods and their impact on ECM integrity, transparency, and mechanical strength. We explored source tissues such as porcine, human, and SMILE-derived lenticules based on their structure similarity and clinical suitability. Characterization techniques including immunohistochemical, histological, mechanical, and in vivo assessments are reviewed to evaluate scaffold quality and biocompatibility. Recellularization approaches which restore corneal functionality, using epithelial, stromal, and endothelial cells also have been investigated. Additionally, progresses in composite biomaterials and 3D bioprinting utilizing decellularized corneal matrices are highlighted, showing enhanced transparency, adhesion, and regenerative potential. Despite clinical progress which is evidenced by successful preclinical studies and clinical trials, some challenges such as protocols optimization, large-scale production, and integration with host tissue remain. Further integrated research is essential to optimize scaffold design, ensure long-term safety, and establish decellularized corneas as a possible solution to the scarcity of donor tissues for transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.